Alpha Tau Medical And 2 Other Penny Stocks Worth Your Attention

In This Article:

As the U.S. stock market surges on news of a trade deal with the UK, investors are keenly observing how such developments might influence various sectors, including smaller-cap stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing opportunities for growth at lower price points despite being considered a somewhat outdated term. By focusing on strong financials and solid fundamentals, these under-the-radar investments can present compelling prospects for those looking to explore beyond the mainstream market options.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Safe Bulkers (NYSE:SB)

$3.39

$358.57M

★★★★☆☆

Tuya (NYSE:TUYA)

$2.29

$1.39B

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.045

$16.42M

★★★★☆☆

Kiora Pharmaceuticals (NasdaqCM:KPRX)

$3.35

$9.9M

★★★★★★

Flexible Solutions International (NYSEAM:FSI)

$3.60

$45.28M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.63

$89.65M

★★★★★★

Heritage Global (NasdaqCM:HGBL)

$1.975

$70.64M

★★★★★★

BAB (OTCPK:BABB)

$0.84

$6.12M

★★★★★★

Lifetime Brands (NasdaqGS:LCUT)

$3.29

$72.4M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.843

$74.37M

★★★★★☆

Click here to see the full list of 767 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Alpha Tau Medical

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company specializing in the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for treating solid cancer, with a market cap of $182.29 million.

Operations: Alpha Tau Medical Ltd. currently has no reported revenue segments as it focuses on developing its diffusing alpha-emitters radiation therapy for solid cancer treatment.

Market Cap: $182.29M

Alpha Tau Medical Ltd. is a pre-revenue company focusing on its innovative Alpha DaRT technology for cancer treatment, recently receiving FDA approval to initiate a pilot study for recurrent glioblastoma. Despite no revenue, the company maintains financial stability with short-term assets of US$64.2 million surpassing liabilities and sufficient cash runway for over two years. The recent follow-on equity offering raised US$36.86 million, potentially bolstering its development efforts but increasing share dilution risk. Though unprofitable with rising losses, the seasoned management team provides experienced leadership in navigating these challenges as they advance clinical trials and product development.